These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24719445)

  • 1. Comparison of commercial antimicrobial susceptibility test methods for testing of Staphylococcus aureus and Enterococci against vancomycin, daptomycin, and linezolid.
    Riedel S; Neoh KM; Eisinger SW; Dam LM; Tekle T; Carroll KC
    J Clin Microbiol; 2014 Jun; 52(6):2216-22. PubMed ID: 24719445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
    Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative study of the susceptibility to daptomycin and other antimicrobials against Staphylococcus spp. resistant to methicillin and Enterococcus spp. using Wider, E-test, and microdilution methods].
    Gómez-Garcés JL; López-Fabal F; Burillo A; Gil Y
    Rev Esp Quimioter; 2010 Jun; 23(2):87-92. PubMed ID: 20559607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
    Rybak MJ; Hershberger E; Moldovan T; Grucz RG
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections.
    Wagenlehner FM; Lehn N; Witte W; Naber KG
    Chemotherapy; 2005 May; 51(2-3):64-9. PubMed ID: 15870498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Hall AD; Steed ME; Arias CA; Murray BE; Rybak MJ
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3174-80. PubMed ID: 22470111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
    Sader HS; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3178-81. PubMed ID: 23629712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
    Barber KE; Smith JR; Raut A; Rybak MJ
    J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.
    Johnson AP; Mushtaq S; Warner M; Livermore DM
    Int J Antimicrob Agents; 2004 Oct; 24(4):315-9. PubMed ID: 15380254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci.
    Tenover FC; Williams PP; Stocker S; Thompson A; Clark LA; Limbago B; Carey RB; Poppe SM; Shinabarger D; McGowan JE
    J Clin Microbiol; 2007 Sep; 45(9):2917-22. PubMed ID: 17634301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of inoculum size on selection of in vitro resistance to vancomycin, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus.
    Rio-Marques L; Hartke A; Bizzini A
    Microb Drug Resist; 2014 Dec; 20(6):539-43. PubMed ID: 25010140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin.
    Rathe M; Kristensen L; Ellermann-Eriksen S; Thomsen MK; Schumacher H
    APMIS; 2010 Jan; 118(1):66-73. PubMed ID: 20041873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
    Steinkraus G; White R; Friedrich L
    J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of vancomycin, linezolid, and daptomycin against staphylococci and enterococci isolated in 5 Greek hospitals during a 5-year period (2008-2012).
    Papadimitriou-Olivgeris M; Kolonitsiou F; Zerva L; Lebessi E; Koutsia C; Drougka E; Sarrou S; Giormezis N; Vourli S; Doudoulakakis A; Konsolakis C; Marangos M; Anastassiou ED; Petinaki E; Spiliopoulou I
    Diagn Microbiol Infect Dis; 2015 Dec; 83(4):386-8. PubMed ID: 26341703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
    LaPlante KL; Rybak MJ; Leuthner KD; Chin JN
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1298-303. PubMed ID: 16569844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of daptomycin and comparator agents against Staphylococcus aureus isolates from intravenous drug users with right endocarditis.
    Sanchez-Porto A; Casanova-Roman M; Casas-Ciria J; Santaella MJ; Sanchez-Morenilla I; Eiros-Bouza JM
    Infez Med; 2010 Jun; 18(2):108-12. PubMed ID: 20610933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daptomycin activity tested against linezolid-nonsusceptible gram-positive clinical isolates.
    Mendes RE; Jones RN; Deshpande LM; Ross JE; Sader HS
    Microb Drug Resist; 2009 Dec; 15(4):245-9. PubMed ID: 19857129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus.
    Saravolatz LD; Pawlak J; Johnson L; Bonilla H; Saravolatz LD; Fakih MG; Fugelli A; Olsen WM
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4478-82. PubMed ID: 22585222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients.
    Rolston KV; Kapadia M; Tarrand J; Coyle E; Prince RA
    Int J Antimicrob Agents; 2013 Jun; 41(6):516-20. PubMed ID: 23481658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Cha R; Brown WJ; Rybak MJ
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3960-3. PubMed ID: 14638509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.